Universitaetsklinikum Muenster AöR
- Address
- Von-Esmarch-Strasse 58, Sentrup, 48149 Munster, Germany
Neurologic and Vascular Research
At Universitaetsklinikum Muenster AöR, clinical trials in cardiovascular disease and diagnostic techniques are exploring better care for people with acute ischemic stroke, high-risk transient ischemic attack, and proximal deep vein thrombosis. These studies focus on testing new treatments and improving how clot-related conditions are managed.
- New therapies aimed at reducing stroke risk and improving recovery
- Treatments designed to support clot dissolution in vein thrombosis
- Research on safer, more effective approaches to vascular disease care
The work combines treatment evaluation with efforts to strengthen diagnosis and risk reduction in urgent vascular conditions.
Oncology and Hematology Studies
This site is active in neoplasm research across digestive system diseases, hemic and lymphatic diseases, and broader cancer care. Trials include studies in esophageal carcinoma, endometrial carcinoma, prostate cancer, acute myeloid leukemia, multiple myeloma, classical Hodgkin lymphoma, and Ewing sarcoma, with a strong emphasis on improving treatment effectiveness and disease control.
- Testing new cancer therapies and combinations for solid tumors
- Evaluating treatment strategies in leukemia, lymphoma, and myeloma
- Studying ways to improve survival, response, and long-term disease management
Several trials at Universitaetsklinikum Muenster AöR are aimed at refining cancer care for both adults and younger patients.
Prostate Cancer Imaging and Treatment Innovation
A major research focus is prostate cancer, including metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, oligometastatic prostate cancer, and PSMA PET scan positive CRPC. These trials are assessing new therapies, hormone-based treatment approaches, and advanced imaging to better detect and monitor disease.
- Evaluating targeted treatments for advanced prostate cancer
- Testing combinations that may improve disease control and survival
- Using PSMA-based imaging to improve detection of spread and guide care
The prostate cancer program blends diagnostic and therapeutic research to support more precise, personalized management.
Pediatric and Adolescent Cancer Research
The site also contributes to studies in children and young adults with cancers such as classical Hodgkin lymphoma, acute myeloid leukemia, and Ewing sarcoma. These trials are designed to improve event-free survival and refine treatment approaches for younger patients facing aggressive disease.
- Optimizing treatment for pediatric and adolescent blood cancers
- Assessing therapy adjustments to improve long-term outcomes
- Supporting research that balances effectiveness with tolerability in younger patients
These studies reflect a strong commitment to advancing age-specific cancer care at Universitaetsklinikum Muenster AöR.
Immune and Targeted Therapy Research
Trials in immune system diseases and cancer are examining new treatment options that harness immunotherapy and targeted agents. Research includes patients with esophageal carcinoma, endometrial carcinoma, and several advanced cancers, with the goal of improving response rates and survival.
- Testing immunotherapy approaches for difficult-to-treat cancers
- Evaluating targeted treatment strategies to slow disease progression
- Studying whether newer combinations can improve overall outcomes
These investigations help expand treatment choices for patients whose cancers need more effective options.
Hematologic and Transplant-Related Research
In hematology, the clinical trial portfolio includes studies in acute myeloid leukemia, multiple myeloma, and other blood cancers, along with research that supports treatment selection and disease monitoring. Some trials also examine how to improve outcomes after intensive therapy or transplant-related care.
- Comparing treatment strategies for leukemia and myeloma
- Studying markers of disease response and residual disease
- Exploring ways to improve survival and reduce relapse risk
This area brings together diagnostic and therapeutic research to improve blood cancer management across different patient groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 35 therapeutic areas and 15 of 619 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 595 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 125 by active trials.
- 1Merck Sharp & Dohme LLC12active
lock +124 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB27trials
lock +85 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Muenster AöR
lock Showing 1 of 533 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 619 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 35 | Unknown | 2015-03-19 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.